drugset / Trial / NCT03248570
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Phase 2
Completed
26 enrolled
University of California, San Francisco
Merck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
Timeline
- Start
- 2018-02-20
- Primary completion
- 2023-09-28
- Completion
- 2023-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Cabazitaxel | Other / unclassified | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Docetaxel | Small molecule | — | — |